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ABSTRACT
Objective: The primary motive behind this investigation is to develop and optimize the solid lipid nanoparticles formulation of enzalutamide for the 
effective drug delivery.
Materials and Methods: The formulation variables were optimized using design of experiments. Box–Behnken design was used for the study and the 
results were analyzed using response surface methodology. The prepared nanoformulation was characterized for particle size, zeta potential, surface 
morphology, X-ray diffractometry (XRD), in vitro drug release kinetics, and stability study.
Results: The influence of formulation variables, drug-to-lipid ratio, concentration of phosphatidylcholine, and concentration of poloxamer 188 were 
evaluated by regression analysis. The optimized formulation (F3) was found to have the minimum particle size (253 nm) with maximum entrapment 
efficiency (89.72%) and drug loading (23.84%). From SEM studies, the data showed a spherical shape for enzalutamide nanoparticles with uniform 
and relatively narrow particle distribution. From XRD examines, it is demonstrative that the drug was not in crystalline form in nanoformulation when 
compared with pure drug. In vitro release studies disclosed that maximum cumulative drug release was attained by F3 (99.72%) in controlled manner. 
The optimized formulation of enzalutamide followed zero-order release kinetics with a strong correlation coefficient (R2 = 0.9994).
Conclusion: The nanoformulation prepared under optimized conditions is in concurrence with the expected results. The SLN formulation can be used 
as a potential carrier for the effective delivery of enzalutamide.
Keywords: Enzalutamide, Box–Behnken design, Prostate cancer, Solid lipid nanoparticle, Trimyristin, Zero-order kinetics.
INTRODUCTION
The emerging field of nanotechnology seeks to exploit distinct 
technological advantages of nanoscience. The booming 
nanotechnologies are supported by massive state investments in 
many countries [1]. Solid lipid nanoparticles (SLNs) are an alternative 
carrier system used to stack the drug for targeting, to improve the 
bioavailability by the enhancement of drug solubility and protection 
against presystemic metabolism. The circumvention of presystemic 
metabolism is attributed to the nanometric size range, which makes the 
drug not to be uptaken by the liver from the delivery system for the 
process of metabolism [2].
SLNs are classically spherical with a mean diameter ranging from 1 
to 1000 nm. It is a substitutive carrier system to traditional colloidal 
carriers such as emulsions, liposomes, and polymeric micro- and 
nano-particle [3]. SLN can be defined as colloidal drug delivery system 
consisting of solid lipid and stabilized with surfactant with particle 
size ranging from 10 nm to 1000 nm [4]. For the preparation of SLN, 
several factors are to be considered which include effect of lipids and 
surfactants [5] processing parameters such as homogenization and 
sonication, formulation parameters such as drug-to-lipid ratio, lipid 
type and concentration, surfactant type, and concentration [6]. Recently, 
much emphasis is being laid on the development of multiparticulate 
dosage forms in comparison to single unit systems due to their 
potential benefits such as increased bioavailability, reduced risk of 
systemic toxicity, reduced risk of local irritation, and predictable gastric 
emptying [7]. Enzalutamide is an orally active inhibitor of the signaling 
pathways mediated by the androgen receptor (AR) that was explicitly 
brought about to overcome castration-resistant prostate cancer (CRPC) 
harboring AR amplification or overexpression. Enzalutamide has 
demonstrated noteworthy activity in men with metastatic CRPC [8].
In the current work, hot homogenization followed by the ultrasonication 
method was employed to prepare the enzalutamide-loaded SLNs 




Tristearin (Dynasan-118), tripalmitin (Dynasan-116), and trimyristin 
(Dynasan-114) were procured from Sigma-Aldrich Chemicals, 
Hyderabad, India. Enzalutamide was a kind gift sample from Dr. Reddy’s 
Labs, India. Poloxamer-188 and egg lecithin were gift samples from 
Aurobindo Labs, India. Solvents and all other chemicals were of 
analytical grade and were used without further purification.
Drug authentication
Fourier-transform infrared spectroscopy (FTIR)
Fourier-transform infrared spectroscopy (FTIR) of enzalutamide was 
done using Tensor 27 FTIR spectrophotometer (Bruker Optics, Germany). 
The samples were scanned over wavenumber region of 4000-400 cm−1 
at resolution of 4 cm−1. Samples were prepared using KBr (spectroscopic 
grade) disks with hydraulic pellet press at pressure of 7–10 tons.
Characterization by differential scanning calorimetry (DSC)
DSC is one of the fundamental techniques employed to determine the 
purity of drug and investigate drug-excipient compatibility. Accurately 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.31617
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weighed amount (5 mg) of drug sample to be analyzed was taken in the 
pierced DSC aluminum pan and scanned in the temperature range of 
50°C–230°C. The heating rate was 20°C/min. The thermogram of drug 
was obtained.
Preliminary experiments
The preliminary experiments (one factor at a time approach) were 
performed to identify the best choice of lipids and surfactants. From the 
results obtained, formulations incorporated with Dynasan-116 displayed 
lower particle sizes, but the polydispersity index (PDI) was high and zeta 
potential (ZP) was low. Formulations constituted by Dynasan-118 exposed 
lower PDI, but higher particle sizes and lower ZP. Formulations containing 
Dynasan-114 demonstrated relatively better size, PDI and ZP in relation to 
other formulations. Based on the results, trimyristin (Dynasan-114) was 
selected as the lipid of choice for further investigations [9].
Drug-excipients compatibility study
The Drug-excipients compatibility studies were performed to check 
and interaction between drug and selected excipients.
Design of experiments
According to Box–Behnken design, a total number of 17 experiments, 
including 12 factorial points at the midpoints of the edges of the 
process space and five replicates at the center point for the estimation 
of pure error sum of squares, were performed to choose the best model 
among the linear, two-factor interaction, and quadratic model due 
to the analysis of variance (ANOVA) F-value. The obtained p<0.05 is 
considered statistically significant.
From the preliminary studies, it was found that the drug-to-lipid ratio 
(A), concentration of phosphatidylcholine (B), and concentration of 
poloxamer 188 (C) had a significant effect on the particle size (Y1), 
entrapment efficiency (Y2), and drug loading (Y3) of SLNs. Therefore, 
by fixing the homogenization time (30 min), stirring time (2 h), and 
sonication time (5 min), the selected variables A, B, and C were studied 
at three different levels as low (−1), medium (0), and high (+1) (Table 1).
The experiments were conducted as for the design and obtained 
responses (Table 2). On the basis of preliminary studies, the 
factors such as drug-to-lipid ratio (1:10–1:20), concentration of 
phosphatidylcholine (50–100 mg), and concentration of poloxamer 
188 (100–200 mg) were identified as the formulation variables. The 
response surfaces of the variables within the experimental field were 
assessed using Stat-Ease Design Expert® software V8.0.1. Subsequently, 
three additional validation experiments were steered to verify the 
validity of the statistical experimental strategies.
Regression analysis
The targeted response parameters were analyzed statistically utilizing 
Stat-Ease Design Expert® programming V8.0.1 by one-way ANOVA at 
0.05 levels. The individual parameters were assessed utilizing the F test 
and quadratic models of the frame Y = β + β1 × 1+ β2 × 2+ β3 × 1X2+ 
β4 × 12+ β5 × 22 were produced for every response parameter utilizing 
multiple linear regression analysis, where Y is the degree of the 
measured response, β is the intercept, and β1 to β2 are the regression 
coefficients. X1 and X2 represent the primary impacts, X1 × 2 is the 
interaction between the fundamental impacts, and X12 and X22 are 
















1 1:15 75 150 241.82 91.23 20.26
2 1:20 50 150 463.56 93.82 24.42
3 1:15 100 200 400.72 77.46 17.72
4 1:10 100 150 262.62 88.93 23.16
5 1:20 75 100 480.42 91.76 22.36
6 1: 15 50 200 274.62 79.12 19.32
7 1: 15 75 150 242.24 90.86 20.48
8 1:10 75 100 254.32 75.32 15.12
9 1: 15 75 150 241.32 91.36 20.12
10 1:20 100 150 492.56 89.82 20.08
11 1:10 75 200 264.72 79.62 18.98
12 1:20 75 200 491.24 88.36 18.24
13 1: 15 100 100 287.32 87.13 22.26
14 1:10 50 150 240.12 69.36 14.28
15 1: 15 75 150 242.06 89.76 21.12
16 1: 15 75 150 242.96 89.32 20.82
17 1: 15 50 100 357.46 70.72 15.13
EE: Entrapment efficiency, DL: Drug loading
Table 1: List of dependent and independent variables in in Box–Behnken design
Independent variables Levels
Variable Name Units Low Middle High
A Drug-to-lipid ratio - 1:10 1:15 1:20
B Concentration of phosphatidylcholine mg 50 75 100
C Concentration of poloxamer 188 mg 100 150 200
Dependent variable Goal
Variable Name Units
Y1 Particle size nm Minimize
Y2 EE Percentage Maximize
Y3 DL Percentage Maximize
EE: Entrapment efficiency, DL: Drug loading
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the quadratic terms of the independent variables that were used to 
simulate the curvature of the designed sample space. The value of 
coefficients reflected the effect of independent variables and their 
interaction on the dependent variables. A positive coefficient indicates 
a synergistic effect; meanwhile, a negative one reflects an antagonistic 
effect. The significance of individual coefficients was determined by 
ANOVA test and was considered significant if p<0.05. A backward 
elimination procedure was implemented to fit the data into different 
predictor equations. The quadratic models engendered by regression 
analysis were used to construct the three-dimensional graphs in which 
response parameter Y was characterized by a curvature surface as a 
function of X [10-12]. The effect of the independent variables on each 
response parameters was visualized from the perturbation plots.
The optimized formulation was obtained which has the minimum 
particle size with maximum entrapment efficiency and drug loading. 
By utilizing the software, the solution for optimized formulation with 
a desirability value of 0.885 was found. The optimized formulation 
was prepared and evaluated for particle size, entrapment efficiency, 
and percentage drug loading. Observe response value of the optimized 
formulation was compared with predicted value. The optimized batch(s) 
were further investigated by X-ray diffractometry (XRD) and SEM.
Preparation of solid lipid nanoparticles (SLNs)
Hot homogenization followed by the ultrasonication method was 
employed to prepare enzalutamide-loaded SLNs. Enzalutamide (dose 
40 mg), lipid, and phosphatidylcholine were dissolved in 5 ml of 1:1 
mixture of chloroform and methanol. Organic solvents were completely 
evaporated using a rotary evaporator (Heidolph, Schwabach, Germany). 
Enzalutamide entrenched lipid layer was liquefied by heating to 5°C 
above melting point of the lipid. Aqueous phase was prepared by 
dissolving poloxamer 188 in double distilled water and heated to same 
temperature (based on lipid melting point) of oil phase. Hot aqueous 
phase was added to the oil phase and homogenization was carried out 
(at 12,000 rpm) using homogenizer (Diax900, Heidolph, Germany) 
for 4 min. The coarse hot oil in water emulsion so obtained was 
ultrasonicated using a 12 T probe Sonicator (Vibra-Cell, Sonics, CT, USA) 
for 20 min. Enzalutamide-loaded solid lipid nanoparticles (SLNs) were 
obtained by allowing hot nanoemulsion to cool to room temperature.
Characterization of solid lipid nanoparticles (SLNs)
Measurement of particle size, polydispersity index (PDI), and zeta 
potential of solid lipid nanoparticles (SLNs)
The size, PDI, and ZP of the SLNs were measured using a zetasizer (Nano 
ZS90, Malvern, Worcestershire, UK). From the prepared SLN dispersion, 
100 ml was diluted to 5 ml with double distilled water to get optimum 
kilo counts per second (Kcps) of 50–200 for measurements.
Determination of entrapment efficiency and drug loading
A fixed quantity of SLNs dispersion (10 ml) was taken in a centrifuge 
tube and centrifuged at 18,000 rpm for 20 min at room temperature 
(Remi Instruments Pvt. Ltd, India). The lipid portion was isolated 
and the absorbance of the drug in the supernatant was determined 
spectrophotometrically at λmax 270 nm (Shimadzu 1800, Japan).
Characterization of crystallinity by powder X-ray diffractometry 
(PXRD)
Powder X-ray diffractometer (Multiflex, M/s. Rigaku, Tokyo, Japan) was 
used for diffraction studies. Powder XRD studies were performed on the 
samples by exposing them to nickel filtered CuKa radiation (40 kV, 30 mA) 
and scanned from 2° to 70°, 2 θ at a step size of 0.045° and step time of 0.5 s. 
Samples used for PXRD analysis were pure enzalutamide, physical mixture 
of drug with lipid (1:1 ratio), and lyophilized enzalutamide-loaded SLNs.
Morphology by scanning electron microscopy (SEM)
The morphology of nanoparticles was studied by scanning electron 
microscope (SEM, Hitachi, Tokyo, Japan). Freeze-dried SLNs of 
enzalutamide were suitably diluted with double distilled water (1 in 100) 
and a drop of nanoparticle formulation was placed on sample holder and 
air dried. Then, the sample was observed at accelerating voltage of 15,000 
volts at various magnifications. Imaging was carried out in high vacuum.
In vitro drug release studies
In vitro release studies were performed using dialysis bag method. 
Dialysis membrane (molecular weight cutoff between 12,000 and 
14,000) was soaked overnight in double distilled water before the release 
studies. Hydrochloric acid (0.1 N) and phosphate buffer pH 6.8 were used 
as release media. The experimental unit consists of a donor and receptor 
compartment. Donor compartment consists of a boiling tube which was 
cut open at one end and tied with dialysis membrane at the other end 
into which SLN dispersion of 3 ml was taken for release study. Receptor 
compartment consists of a 250 ml beaker which was filled with 100 ml 
release medium and the temperature of it was maintained at 37°C ± 
0.5°C. At 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h time points, 3 ml samples 
each were withdrawn from receiver compartment and replenished with 
the same volume of release medium. The collected samples were suitably 
diluted and analyzed by UV-visible spectrophotometer at 236 nm.
Drug release kinetics
To elucidate the mode and mechanism of drug release, the data from 
the in vitro release study were fitted into various kinetic models such as 
zero-order, first-order, Higuchi’s, and Korsmeyer–Peppas model.
Stability studies
Stability of enzalutamide nanoparticles suspension in screw-capped 
glass vials was evaluated over a time period of 90 days. Six samples were 
divided into two groups and stored at 25°C and 4°C. Drug leakage from 
nanoparticles and mean particle size of the samples were determined 
at the end of 1, 7, 15, 30, 45, 60, and 90 days.
Data analysis
Data are expressed as the means ± standard deviation (SD) of the mean 
and statistical analysis was carried out employing the one-way analysis 




The FTIR spectrum of enzalutamide sample recorded. The characteristic 
peaks of enzalutamide are seen at 3433, 3095, 2951, 2233, 1763, 1607, 
1499, 1270, 1136, 1052, 998, and 786 cm−1. The presence of prominent 
peaks confirms the purity of drug as per established standards (Fig. 1).
Preliminary experiments
Preliminary experiments conducted using three different lipids 
Trimyristin (Dynasan-114), tripalmitin (Dynasan-116), and tristearin 
Fig. 1: Fourier-transform infrared spectroscopy spectrum of 
enzalutamide pure drug
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(Dynasan-118). Based on the results from the initial studies, trimyristin 
(Dynasan-114) was selected as the lipid for the further studies.
Drug-excipients compatibility study
Fourier-transform infrared spectroscopy
To test for possible intermolecular interaction between enzalutamide 
and the selected lipid trimyristin (Dynasan-114), FTIR was carried 
out. The FTIR spectra analysis of enzalutamide alone showed that 
the principal peaks were observed at wavenumbers 3433, 3095, 
2951, 2233, 1763, 1607, 1499, 1270, 1136, 1052, 998, and 786 cm−1 
confirming the purity of drug as per established standards (Fig. 1). In 
the IR spectra of the physical mixture of enzalutamide with trimyristin 
(Dynasan-114), the major peaks of enzalutamide were observed at 
same wavenumbers (Fig. 2). However, some additional peaks were 
observed with physical mixture, which could be due to the presence of 
functional groups of lipid.
Differential scanning calorimetry
The thermoanalytical graph obtained by DSC, a sharp symmetric 
endothermic peak was observed at 203°C for pure enzalutamide which 
corresponds to its melting point (Fig. 3). The DSC curve of physical mixture 
exhibits two endothermic peaks at 63.62°C and 203°C corresponding 
to characteristic peaks of lipid and drug, respectively (Fig. 4). The 
characteristic peak of drug is not altered with the physical mixture. This 
indicates the compatibility of the drug with the selected lipid.
Analysis of data
Seventeen experiments were essential for the response surface 
methodology based on the Box–Behnken design. Founded on the 
experimental design, the factor combinations generated different 
responses (Table 2). These results evidently postulate that the dependent 
variables are strongly dependent on the selected independent variables 
as they show a wide variation among all the 17 batches.
Data were analyzed using Stat-Ease Design Expert® software V8.0.1 
to obtain analysis of variance (ANOVA), regression coefficients, and 
regression equation. Mathematical relationships were generated 
using multiple linear regression analysis for the mentioned variables 
(Table 3).
The particle size of the nanoparticles was noticed to be in the range of 
240.12–492.56 nm (Table 2). The mathematical model generated for 
particle size (Y1) was found to be significant with F-value of 10953.34 
implies that the model is significant (Table 3). Results of the equation 
specify that the impact of A is more substantial than B and C. The 
influence of the main and interactive effects of independent variables 
on the particle size was additionally explicated using the perturbation, 
3D response surface plots. The perturbation plot (Fig. 5) showing the 
main effects of A, B, and C on the particle size (Y1). This figure clearly 
shows that A has the main and the major effect on Y1 followed by B 
and C which have moderate effect on Y1. The relationship between the 
dependent and independent variables was further elucidated using 3D 
response surface plots and corresponding contour plots (Fig. 6a and b). 
At low levels of A, Y1 increased from 240.12–264.72 nm. Similarly, at 
high levels of A, Y1 increased from 463.56 to 492.56 nm. At low levels of 
B, Y1 increased from 240.12 to 463.56 nm. Similarly, at high levels of B, 
Y1 increased from 262.62 to 492.46 nm. At low levels of C, Y1 increased 
from 254.32 to 480.42 nm. Similarly, at high levels of C, Y1 increased 
from 264.72 to 491.24 nm. Entrapment efficiency of nanoparticles was 
found to be in the range of 69.36–93.82% (Table 2).
The effect of A (drug-lipid ratio) is more significant than B, whereas the 
variable C (concentration of poloxamer 188) was found to have negative 
effect on the entrapment efficiency, which means this factor is inversely 
proportional to the response. The influence of the main and interactive 
effects of independent variables on the entrapment efficiency was 
further elucidated using the perturbation and 3D response surface 
Fig. 2: Fourier-transform infrared spectroscopy spectrum of 
enzalutamide pure drug + Dynasan-114
Fig. 3: Differential scanning calorimetry thermogram of 
enzalutamide pure drug
Fig. 4: Differential scanning calorimetry thermogram of 
enzalutamide pure drug + Dynasan-114
Fig. 5: Perturbation plot showing the effect of A, B, and C on 
particle size
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plots (Fig. 7). It is found that all the variables are having negative 
interactive effects for the response Y2. The 3D response surface plots of 
the response Y2 portray the interactive effects of independent variables 
on response Y2, one variable was kept constant while the other two 
variables varied in a certain range. The shapes of response surfaces 
plots reveal the nature and extent of the interaction between different 
factors. The interaction between A and B on entrapment efficiency at 
a fixed level of C is shown in Fig. 8a. The interaction between B and C 
on entrapment efficiency at a fixed level of A is shown in Fig. 8b. The 
interaction between A and C on entrapment efficiency at a fixed level 
of B is shown in Fig. 8c. At low levels of A, Y2 increased from 69.36% 
to 88.93%. Similarly, at high levels of A, Y2 increased from 88.36% 
to 93.82%. At low levels of B, Y2 increased from 69.36% to 93.82%. 
Similarly, at high levels of B, Y2 increased from 77.46% to 89.82%. At 
low levels of C, Y2 reduced from 91.76% to 70.72%. Similarly, at high 
levels of C, Y2 reduced from 88.36% to 77.46%.
Percent drug loading of nanoparticles was found to be in the range 
of 14.28%–24.42% (Table 2). Results indicate that A and B have 
positive effect on drug loading. The effect of A (drug-lipid ratio) is 
more significant than B, whereas the variable C (concentration of 
poloxamer 188) was found to have negative effect on the drug loading, 
which means this factor is inversely proportional to the response. The 
influence of the main and interactive effects of independent variables 
on the drug loading was further elucidated using the perturbation 
and 3D response surface plots. The individual main effects of A, B, 
and C on drug loading show that all the variables are having negative 
interactive effects for the response Y3 (Fig. 9). The shapes of response 
surfaces plots reveal the nature and extent of the interaction between 
different factors. The interaction between A and B on drug loading at a 
fixed level of C is shown in Fig. 10a. The interaction between A and C on 
drug loading at a fixed level of B is shown in Fig. 10b. The interaction 
between B and C on drug loading at a fixed level of A is shown in Fig. 
10c. At low levels of A, Y3 increased from 14.28% to 23.16%. Similarly, 
at high levels of A, Y3 increased from 18.24% to 24.42%. At low levels 
of B, Y3 increased from 14.28% to 24.42%. Similarly, at high levels of 
B, Y3 increased from 17.72% to 23.26%. At low levels of C, Y3 reduced 
from 22.36% to 15.12%. Similarly, at high levels of C, Y3 reduced from 
19.32% to 17.72%.
Optimization and confirmation experiments
A numerical optimization technique using the desirability approach 
was employed to prepare enzalutamide nanoparticles with the desired 
responses. Constraints such as minimizing the particle size in addition 
to maximizing the entrapment efficiency and drug loading were set 
as goals to locate the optimum settings of independent variables. The 
optimized levels and predicted values of Y1, Y2, and Y3 are tabulated 
(Table 4). To verify these values, three batches of nanoparticles were 
prepared according to the predicted levels of A, B, and C. The predicted 
Table 3: Regression equations for the responses – particle size, 
entrapment efficiency, and drug loading
Response Regression equation
Y1 242.08+113.25 A+13.43 B+6.47 C+1.63 
AB+49.06 BC+82.64 A2+40 B2+47.95 C2
Y2 90.53+6.32 A+3.79 B−0.046 C−5.89 
AB – 1.93 AC−4.52 BC−5.09 B2−6.80 C2
Y3 20.53+1.70 A+1.26 B−0.076 C−3.31 
AB−2.00 AC−2.18 BC−1.89 C2
Fig. 7: Perturbation plot showing the effect of A, B, and C on 
percentage entrapment efficiency
Fig. 6: (a) Response surface plot showing the influence of 
drug-to-lipid ratio and concentration of phosphatidylcholine 
on particle size at constant level of C. (b) Response surface plot 
showing the influence of concentration of phosphatidylcholine 




Table 4: Optimized values obtained by the constraints applies on Y1, Y2, and Y3
Independent variable Nominal 
values
Predicted values Observed values
Particle size (Y1) EE (Y2) DL (Y3) Batch Particle size (Y1) EE (Y2) DL (Y3)
Drug-lipid ratio (A) 1:12.05 243.89 89.198 23.09 F1 248.8 88.24 23.24
F2 258.3 89.46 22.62
Concentration of 
phosphatidylcholine (B)




EE: Entrapment efficiency, DL: Drug loading
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and observed values tabulated (Table 4). Obtained Y1, Y2, and Y3 values 
were in a close agreement with the predicted values. This demonstrated 
the reliability of the optimization procedure in predicting the operating 
parameters for the preparation of enzalutamide nanoparticles. All the 
three batches of obtained enzalutamide nanoparticles were subjected 
to further characterization.
All the prepared formulations were analyzed to determine their particle 
size distribution, ZP. A particle size, size distribution, and ZP curve of 
optimized formulations obtained (Figs. 11 and 12). The mean size 
of all the formulations was ranging from 248.8 ± 6.3 nm to 258.3 ± 
9.8 nm (Table 5). The PDI was ranging from 0.198 to 0.251, indicating 
the narrow size distribution. The SLN formulations exhibited negative 
surface charge with the inclusion of enzalutamide which clearly 
suggested the orientation of enzalutamide in the lipid matrix. The 
surface charge is a key factor for the stability of colloidal dispersion. In 
our case, the ZP values of SLN formulations were found to be in between 
28.7 ± 5.48 mV and 29.3 ± 4.89 mV. ZP is an important factor that affects 
the stability of colloidal systems. Total entrapment efficiency of the 
nanoparticles formulations was determined and found to be ranging 
from 88.24 ± 0.37% to 89.72 ± 0.18%. The percent drug loading of 
the formulations was found to be in the range from 23.24 ± 0.12% to 
23.84 ± 0.32%.
Powder X-ray diffractometry
Powder XRD patterns of enzalutamide showed sharp peaks at 2 θ 
scattered angles of 0, 8.5, 12.2, 13.3, 14.1, 17.3, 18.8, 19, 19.6, 20, 21.6, 
22.4, 23.2, 24.2, 24.6, 26, 26.8, and 27.3°, indicating the crystalline 
nature of drug (Fig. 13). These characteristic peaks of enzalutamide 
existed in physical mixtures (Fig. 14), and drug peaks were absent in 
the lyophilized sample (Fig. 15). This indicated that the drug was not in 
crystalline form after lyophilization of SLN. Intensity of pure lipid peaks 
was also decreased in the lyophilized samples.
Surface morphology
Scanning electron microscopy was used to evaluate the morphology of 
the optimized formulation F3. The data showed a spherical shape for 
enzalutamide nanoparticles with uniform and relatively narrow particle 
distribution (Fig. 16). Spherical particles could be uptaken easier than 
disfigured ones. Therefore, it is speculated that the mean particle size 
that was obtained using the laser diffraction method belongs to the 
agglomerated nanoparticles.
Drug release study
Cumulative release (%) of control pure drug enzalutamide within 24 h 
was obtained to be 29.56 which indicate a slow release pattern very less 
drug release for the control (Fig. 17). The slow release of enzalutamide 
can be attributed to the limited solubility. The complete and controlled 
release of the drug from the optimized SLN formulations can be due to 
the reduced particle size and enhanced effective surface area (Table 6).
Drug release kinetics
Release data for optimized formulation (F3) were fitted into various 
kinetic equations to find out the order and mechanism of drug release 
[Figs. 18-21]. Kinetic analysis of drug release profiles showed that 
the systems predominantly released enzalutamide in a zero-order 
Fig. 9: Perturbation plot showing the effect of A, B, and C on 
percentage drug loading
Fig. 8: (a) Response surface plot showing the influence of drug-lipid ratio and concentration of phosphatidylcholine on entrapment 
efficiency at constant level of C. (b) Response surface plot showing the influence concentration of phosphatidylcholine and concentration 
of poloxamer 188 on entrapment efficiency at constant level of A. (c) Response surface plot showing the influence drug-lipid ratio and 
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manner with a strong correlation coefficient (R2 = 0.9994). This was 
corroborated by “n” values of 0.9494 (n > 0.89) which implies Super 
Case II release kinetics (a strong indication of zero order). Zero-order 
release is the ideal in controlled drug release and has been reported 
not to be common with matrix systems, this being attributed to time-
dependent changes in drug depleted matrix surface area and diffusional 
path length. Zero-order release has a lot of advantages including 
ability to deliver drug at a constant rate, thus providing a predictable 
bioavailability status.
Stability study
The purpose of stability testing is to provide the evidence on how 
the quality of drug substance or drug product varies with time 
under the influence of variety of environmental factors such as 
temperature, humidity, and light. No significant difference (p<0.05) 
was found in entrapment efficiency and particle size of optimized 
formulation F3 stored at refrigerated conditions and at room 
temperature (Table 7).
CONCLUSION
Enzalutamide is poorly water-soluble drug with poor oral 
bioavailability due to extensive first-pass metabolism. SLNs of 
enzalutamide were produced by hot homogenization followed 
by an ultrasonication method with the use of a 3-factor, 3-level 
Box–Behnken design. Trimyristin (Dynasan-114), tripalmitin 
(Dynasan-116), and tristearin (Dynasan-118) were used as lipids 
and based on the results from the initial studies, trimyristin 
(Dynasan-114) was selected as the lipid for the further studies 
along with phosphatidylcholine as surfactant and poloxamer 188 as 
stabilizer. The optimized formulation (F3) was obtained which has 
the minimum particle size (253 nm) with maximum entrapment 
efficiency (89.72%) and drug loading (23.84%). The optimized 
batch(s) was further investigated by XRD, SEM, and stability. In 
vitro release studies showed that maximum cumulative drug release 
was obtained for F3 (99.72%) in controlled manner. The optimized 
formulation enzalutamide followed zero-order release kinetics with 
a strong correlation coefficient (R2 = 0.9994). The obtained results 
Table 5: The mean particle size, polydispersity index, zeta potential, entrapment efficiency, and percentage drug loading of optimized 
formulations
Batch MPS±SD (nm) PDI ZP±SD (mV) Percentage EE±SD Percentage DL±SD
1 248.8±6.3 0.206 -28.7±5.48 88.24±0.37 23.24±0.12
2 258.3±9.8 0.251 -28.9±7.79 89.46±0.17 22.62±0.42
3 253±4.2 0.198 -29.3±4.89 89.72±0.18 23.84±0.32
PDI: Polydispersity index, SD: Standard deviation, ZP: Zeta potential, EE: Entrapment efficiency, MPS: Mean particle size, DL: Drug loading
Table 6: Dissolution profile of enzalutamide solid lipid 
nanoparticles (optimized batches)
Time (h) Percentage CDR
Control F1 F2 F3
0 0 0 0 0
1 5.72 5.12 5.98 4.88
2 7.16 9.13 10.19 8.96
3 9.36 13.78 13.12 12.67
4 11.12 17.18 16.88 17.06
5 13.34 21.65 21.1 20.68
6 15.12 25.59 25.26 25.42
7 17.78 30.89 30.29 30.66
8 19.04 35.27 34.36 34.83
9 21.13 39.74 39.14 38.72
10 23.34 43.63 42.38 43.04
11 25.12 46.13 45.93 46.02
12 26.23 49.69 50.12 50.26
16 28.13 65.55 66.54 67.12
20 28.72 81.65 82.34 83.08
24 29.56 99.12 99.28 99.72
CDR: Cumulative drug release
Fig. 10: (a) Response surface plot showing the influence of drug-lipid ratio and concentration of phosphatidylcholine on drug loading at constant 
level of C. (b) Response surface plot showing the influence drug-lipid ratio and concentration of poloxamer188 on drug loading at constant level 
of B. (c) Response surface plot showing the influence concentration of phosphatidylcholine and concentration of poloxamer188 on drug loading at 
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are indicative of enzalutamide SLNs as potential lipid carriers for the 
effective delivery of enzalutamide.
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Table 7: Particle size and entrapment efficiency of enzalutamide optimized formulation F3 after 90 days of storage at refrigerated and 
room temperature
Temperature (°C) Particle size (nm) EE (%) Release data (percentage CDR)
0 month 3 months 0 month 3 months 0 month 3 months
2 h 4 h 2 h 4 h
4±1 248.8±6.3 249.12±5.13 88.24±0.37 67.892±1.13 9.13±0.52 17.18±0.82 8.92±2.12 17.12±1.15
25±2 248.8±6.3 249.76±4.27 88.24±0.37 68.142±0.68 9.18±0.46 17.23±0.32 8.76±0.16 16.89±2.26
n=3 (P<0.05). CDR: Cumulative drug release, EE: Entrapment efficiency
Fig. 11: Particle size distribution of enzalutamide solid lipid 
nanoparticles
Fig. 12: Zeta potential of enzalutamide solid lipid nanoparticles
Fig. 13: X-ray diffraction pattern of pure drug enzalutamide
Fig. 14: X-ray diffraction pattern of physical mixture
Fig. 15: X-ray diffraction pattern of enzalutamide 
nanoformulation F3
Fig. 16: Scanning electron microscopy images of enzalutamide 
nanoformulation F3
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Fig. 17: In vitro release of enzalutamide from nanoformulations 
with pure drug
Fig. 18: Plot of zero-order release kinetics of the optimized batch 
F3
Fig. 19: Plot of first-order release kinetics of the optimized batch 
F3
Fig. 20: Plot of Higuchi release kinetics of the optimized batch F3
Fig. 21: Plot of Korsmeyer–Peppas release kinetics of the 
optimized batch F3
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